A Study of Teduglutide in Japanese People With Short Bowel Syndrome

Launched by TAKEDA · Aug 23, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a medication called teduglutide (also known as Revestive) to see how well it helps people with Short Bowel Syndrome (SBS) and to check for any side effects. Short Bowel Syndrome is a condition that affects the body's ability to absorb nutrients because of a shortened intestine. The trial is open to anyone in Japan who has been treated with teduglutide, and there are no specific exclusions, which means most people with this condition can participate.

During the study, participants will receive injections of teduglutide just under the skin, and doctors will monitor them for side effects for up to three years. Since this is a post-marketing surveillance study, it aims to gather more information about the medication's effects in a real-world setting, outside of the initial clinical trials. If you or a loved one is interested in participating, you could help researchers understand how well this treatment works for people living with Short Bowel Syndrome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All participants in Japan who received teduglutide will be enrolled in this post marketing surveillance.
• Exclusion Criteria:
• • None